Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479010 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01479010 is a Phase 1 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 2 participants.
The verdict
NCT01479010, a Phase 1 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra (recombinant human Interleukin-1 receptor antagonist.
Interventions
- DRUG Anakinra 100 mg subcutaneously daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479010
The ClinicalTrials.gov registry entry for NCT01479010 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anakinra 100 mg subcutaneously daily is the first listed.
NCT01479010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479010 about?
NCT01479010 is a clinical study titled "Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Pulmonary Hypertension". This is an open-label non-randomized, pilot study to evaluate the effect of Interleukin-1 blockade on exercise capacity in patients with pulmonary hypertension. Subjects will undergo cardiopulmonary exercise testing at baseline, and after 4 weeks treatment with Anakinra (recombinant human Interleuki...
What is the current status of trial NCT01479010?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2011-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01479010?
The interventions under investigation include: Anakinra 100 mg subcutaneously daily (DRUG).
Who is sponsoring clinical trial NCT01479010?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.